From:
*Cryptosporidium* and *Giardia* in Africa: current and future challenges

Country | Patient group |
Assemblage (Prevalence in %) ^{a}
| Subtype | Reference |
---|---|---|---|---|

Algeria | Children (8 and 13 years) | A (37.5) |
AI; AII^{b}; Novel subtype
| [119] |

B (56.3) | BIII; BIV; Novel subtypes | |||

A + B (6.3) | ||||

Central African Republic | Dzanga-Sangha Protected Areas Park employees | A (100) | AII | [122] |

Côte d’Ivoire | Patients with intestinal disorders (2–63 years) | A (19.6) | [106] | |

B (76.8) | ||||

A + B (3.6) | ||||

Côte d’Ivoire | Patients with intestinal disorders (2–63 years) | A (34.4) | [106] | |

B (59.0) | ||||

A + B (6.6) | ||||

Egypt | Diarrhoeal patients (2–70 years) | A (6.7) | AI/AII | [121] |

B (80.0) |
BIII; B/BIII; BIV; BIII/BIV^{b}
| |||

A + B (6.7) | ||||

C (6.7) | ||||

Egypt | Diarrhoeal patients (All ages) | A (18.8) | [132] | |

B (81.2) | ||||

Egypt | Children (< 10 years) | A (30.4) | AII | [80] |

B (52.2) | ||||

E (8.7) | ||||

A/B (4.3) | ||||

A/E (4.3) | ||||

Egypt | Children (5–12 years) | A (77.1) | AII | [167] |

B (22.9) | BIII | |||

Egypt | Children with and without diarrhoea (1.5–12 years) | E (100) | [169] | |

Egypt | Diarrhoeal patients (4–65 years) | A (75.6) |
AI^{b}; AII
| [165] |

B (19.5) | ||||

A + B (5.0) | ||||

Egypt | Humans | A (5.0) | [168] | |

B (80.0) | ||||

E (15.0) | ||||

Ethiopia | Children (6–15 years) | A (17.9) |
AII^{b}; AII/AIII
| [103] |

B (82.1) |
BIII; BIV^{b}; BIII/BIV
| |||

Ethiopia | Children (≤ 14 years) | A (22.9) |
AII^{b}
| [301] |

B (77.1) |
BIV; Novel subtypes^{b}
| |||

Ethiopia | Hospital patients (0.5–80 years) | B (100) |
BIII; BIV^{b}
| [99] |

Ethiopia | Human isolates from urban and rural areas | A (52.5) | [164] | |

B (22.0) | ||||

A + F (11.9) | ||||

A + B (13.6) | ||||

Ghana | Children (≤ 5 years) | B (100) | BIII | [305] |

Guinea-Bissau | Children (8.3 months to 7.5 years) | A (11.5) | AII | [309] |

B (84.6) | ||||

Kenya | Diarrhoeal children (≤ 5 years) | A (1.4) | AII | [313] |

B (88.9) |
BIII; BIV; BIII/BIV^{b}
| |||

A + B (9.7) | ||||

Morocco | Urban and rural school children (5–15 years) | A (18.1) | AII | [318] |

B (81.8) |
BIII; BIV^{b}
| |||

Nigeria | Hospital patients (2 months to 70 years) | A (100) | AII | [166] |

Rwanda | Largely asymptomatic children (< 5 years) | A (13.5) |
AI; AII^{b}
| [22] |

B (85.9) | ||||

A + B (0.5) | ||||

Rwanda | Children (< 5 years) | A (14.0) | [24] | |

B (86.0) | ||||

São Tomé and Príncipe | Children (2 months to 10 years) | A (55.5) | [96] | |

B (45.5) | ||||

Tanzania | Diarrhoeal and non-diarrhoeal outpatients (≤ 71 years) | A (6.7) | [340] | |

B (88.8) | ||||

A + B (4.5) | ||||

Tanzania | Diarrhoeal children and controls (< 2 years) | A (50.0) | [72] | |

B (50.0) | ||||

Tanzania | Primary school children | A (21.4) | AII | [123] |

B (78.6) |
BIII; BIV^{b}
| |||

Uganda | Individuals living around Kibale National Park | A | AII | [120] |

B | BIII; BIV | |||

Uganda | Apparently healthy children (0–12 years) | A (14.7) | AII | [345] |

B (73.5) | ||||

A + B (11.8) | ||||

Uganda | Individuals sharing gorilla habitats | A (100) | [163] |